Median serum Shh (=0.001), IL-6 (p = 0.001) levels, tumor burden (p = 0.020), tumor progression (p-0.031), and lymph node status (p = 0.01) were associated with significant prognostic value and early EFS and shorter survival when elevated. This evidence concerns the gene SHH and neoplasm.